CAW
TVRD

Cornerstone Advisors (Washington)’s Tvardi Therapeutics TVRD Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$1K Buy
2
+1
+100% +$581 ﹤0.01% 703
2020
Q2 		$1K Buy
+1
New +$552 ﹤0.01% 694

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cornerstone Advisors (Washington)'s TVRD Position: Q3 2020 in Review

Cornerstone Advisors (Washington) increased its Tvardi Therapeutics (TVRD) stake by 100% in Q3 2020, buying an estimated $581 and bringing the position to 2 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #703.

Cornerstone Advisors (Washington) first reported a position in TVRD in Q2 2020 and has held it in 2 quarters since. 161 funds tracked by Wall St. Rank hold TVRD as of Q3 2020.

  • Cornerstone Advisors (Washington) held 2 shares of Tvardi Therapeutics worth $1K as of Q3 2020.
  • Cornerstone Advisors (Washington) bought 1 Tvardi Therapeutics share in Q3 2020, an estimated $581.
  • Tvardi Therapeutics made up ﹤0.01% of Cornerstone Advisors (Washington)'s portfolio in Q3 2020, its #703 holding.
  • Cornerstone Advisors (Washington) first reported a position in Tvardi Therapeutics in Q2 2020 and has held it in 2 quarters since.
  • 161 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.